The anti-inflammatory activities of Staphylococcus aureus

Trends in Immunology

Volumn 28, Issue 9, 2007, Pages 408-418

  Chavakis, Triantafyllos ^a   Preissner, Klaus T ^b   Herrmann, Mathias ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; CATHELICIDIN; LYSOZYME; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; CELL ADHESION; CELL HOMING; CHEMOTAXIS; COMPLEMENT ACTIVATION; HOSPITAL INFECTION; HOST; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PHAGOCYTE; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; HUMANS; INFLAMMATION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 34548566416     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2007.07.002     Document Type: Review

References (110)

1. Lowy F.D. Staphylococcus aureus infections. New Engl. J. Med. 339 (1998) 520-532
2. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1 (2001) 147-155
3. Carleton H.A., et al. Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J. Infect. Dis. 15 (2004) 1730-1738
4. O'Riordan K., and Lee J.C. Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 17 (2004) 218-234
5. Dinges M.M., et al. Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev. 13 (2000) 16-34
6. Chavakis T., et al. Staphylococcus aureus interactions with the endothelium: the role of bacterial 'secretable expanded repertoire adhesive molecules' (SERAM) in disturbing host defense systems. Thromb. Haemost. 94 (2005) 278-285
7. Foster T.J., and Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 6 (1998) 484-488
8. Mazmanian S.K., et al. Staphylococcus aureus sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5510-5515
9. Foster T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3 (2005) 948-958
10. Rooijakkers S.H., et al. Staphylococcal innate immune evasion. Trends Microbiol. 13 (2005) 596-601
11. Proft T., and Fraser J.D. Bacterial superantigens. Clin. Exp. Immunol. 133 (2003) 299-306
12. Rooijakkers S.H., and van Strijp J.A. Bacterial complement evasion. Mol. Immunol. 44 (2007) 23-32
13. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3 (2003) 710-720
14. Peschel A. How do bacteria resist human antimicrobial peptides?. Trends Microbiol. 10 (2002) 179-186
15. Jin T., et al. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol. 172 (2004) 1169-1176
16. Collins L.V., et al. Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis. 186 (2002) 214-219
17. Sieprawska-Lupa M., et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother. 48 (2004) 4673-4679
18. Braff M.H., et al. Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis. J. Infect. Dis. 195 (2007) 1365-1372
19. Bera A., et al. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol. Microbiol. 55 (2005) 778-787
20. Sahu A., and Lambris J.D. Complement: more than a 'guard' against invading pathogens?. Immunol. Rev. 180 (2001) 35-48
21. Gasque P. Complement: A unique innate immune sensor for danger signals. Mol. Immunol. 41 (2004) 1089-1098
22. Lindahl G., et al. Human complement regulators: a major target for pathogenic microorganisms. Curr. Opin. Immunol. 12 (2000) 44-51
23. Cedergren L., et al. Mutational analysis of the interaction between staphylococcal protein A and human IgG1. Protein Eng. 6 (1993) 441-448
24. Patel A.H., et al. Virulence of protein A-deficient and alpha-toxin-deficient mutants of Staphylococcus aureus isolated by allele replacement. Infect. Immun. 55 (1987) 3103-3110
25. Palmqvist N., et al. Protein A is a virulence factor in Staphylococcus aureus arthritis and septic death. Microb. Pathog. 33 (2002) 239-249
26. Jonsson P., et al. Virulence of Staphylococcus aureus in a mouse mastitis model: studies of alpha hemolysin, coagulase, and protein A as possible virulence determinants with protoplast fusion and gene cloning. Infect. Immun. 49 (1985) 765-769
27. Gomez M.I., et al. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat. Med. 10 (2004) 842-848
28. Gomez M.I., et al. Staphylococcus aureus protein A activates TACE through EGFR-dependent signaling. EMBO J. 26 (2007) 701-709
29. Labandeira-Rey M., et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 315 (2007) 1130-1133
30. Rooijakkers S.H., et al. Anti-opsonic properties of staphylokinase. Microbes Infect. 7 (2005) 476-484
31. Williams R.J., et al. Identification of a novel gene cluster encoding staphylococcal exotoxin-like proteins: characterization of the prototypic gene and its protein product, SET1. Infect. Immun. 68 (2000) 4407-4415
32. Arcus V.L., et al. The three-dimensional structure of a superantigen-like protein, SET3, from a pathogenicity island of the Staphylococcus aureus genome. J. Biol. Chem. 277 (2002) 32274-32281
33. Langley R., et al. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-FcαRI binding and serum killing of bacteria. J. Immunol. 174 (2005) 2926-2933
34. Palma M., et al. Lack of the extracellular 19-kilodalton fibrinogen-binding protein from Staphylococcus aureus decreases virulence in experimental wound infection. Infect. Immun. 64 (1996) 5284-5289
35. Lee L.Y., et al. Inhibition of complement activation by a secreted Staphylococcus aureus protein. J. Infect. Dis. 190 (2004) 571-579
36. Lee L.Y., et al. Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb). J. Biol. Chem. 279 (2004) 50710-50716
37. Hammel M., et al. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 8 (2007) 430-437
38. Rooijakkers S.H., et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 6 (2005) 920-927
39. Luster A.D., et al. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 6 (2005) 1182-1190
40. McEver R.P. Selectins: lectins that initiate cell adhesion under flow. Curr. Opin. Cell Biol. 14 (2002) 581-586
41. Yonekawa K., and Harlan J.M. Targeting leukocyte integrins in human disease. J. Leukoc. Biol. 77 (2005) 129-140
42. Chavakis T., et al. Leukocyte trans-endothelial migration: JAMs add new pieces to the puzzle. Thromb. Haemost. 89 (2003) 13-17
43. Shaw S.K., et al. Coordinated redistribution of leukocyte LFA-1 and endothelial cell ICAM-1 accompany neutrophil transmigration. J. Exp. Med. 200 (2004) 1571-1580
44. Imhof B.A., and Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat. Rev. Immunol. 4 (2004) 432-444
45. Rot A., and von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22 (2004) 891-928
46. Murdoch C., and Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 95 (2000) 3032-3043
47. Schmitz F.J., et al. Delta-toxin from Staphylococcus aureus as a costimulator of human neutrophil oxidative burst. J. Infect. Dis. 176 (1997) 1531-1537
48. Mehlin C., et al. An inflammatory polypeptide complex from Staphylococcus epidermidis: isolation and characterization. J. Exp. Med. 189 (1999) 907-918
49. Gresham H.D., et al. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J. Immunol. 164 (2000) 3713-3722
50. + T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 10408-10413
51. Bestebroer J., et al. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood 109 (2007) 2936-2943
52. Harraghy N., et al. The adhesive and immunomodulating properties of the multifunctional Staphylococcus aureus protein Eap. Microbiology 2003 (2003) 2701-2707
53. Harraghy N., et al. sae is essential for expression of the staphylococcal adhesins Eap and Emp. Microbiology 151 (2005) 1789-1800
54. Palma M., et al. Adherence of Staphylococcus aureus is enhanced by an endogenous secreted protein with broad binding activity. J. Bacteriol. 181 (1999) 2840-2845
55. Hansen U., et al. The anchorless adhesin Eap (extracellular adherence protein) from Staphylococcus aureus selectively recognizes extracellular matrix aggregates but binds promiscuously to monomeric matrix macromolecules. Matrix Biol. 25 (2006) 252-260
56. McGavin M.H., et al. Identification of a Staphylococcus aureus extracellular matrix-binding protein with broad specificity. Infect. Immun. 61 (1993) 2479-2485
57. Hussain M., et al. Insertional inactivation of Eap in Staphylococcus aureus strain Newman confers reduced staphylococcal binding to fibroblasts. Infect. Immun. 70 (2002) 2933-2940
58. Chavakis T., et al. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat. Med. 8 (2002) 687-693
59. Haggar A., et al. The extracellular adherence protein from Staphylococcus aureus inhibits neutrophil binding to endothelial cells. Infect. Immun. 72 (2004) 6164-6167
60. Madsen S.M., et al. Bacterial colonization and healing of venous leg ulcers. APMIS 104 (1996) 895-899
61. Athanasopoulos A.N., et al. The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms. Blood 107 (2006) 2720-2727
62. Sobke A.C., et al. The extracellular adherence protein from Staphylococcus aureus abrogates angiogenic responses of endothelial cells by blocking Ras activation. FASEB J. 20 (2006) 2621-2623
63. Lee L.Y., et al. The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell-mediated responses. J. Clin. Invest. 110 (2002) 1461-1471
64. Xie C., et al. Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus. J. Exp. Med. 203 (2006) 985-994
65. Lebedeva T., et al. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr. Opin. Immunol. 17 (2005) 251-258
66. Verdrengh M., et al. Role of intercellular adhesion molecule 1 in pathogenesis of staphylococcal arthritis and in host defense against staphylococcal bacteremia. Infect. Immun. 64 (1996) 2804-2807
67. Katada T., and Ui M. Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 3129-3133
68. Coenjaerts F.E., et al. Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensitization. J. Immunol. 167 (2001) 3988-3995
69. Rahimpour R., et al. Bacterial superantigens induce down-modulation of CC chemokine responsiveness in human monocytes via an alternative chemokine ligand-independent mechanism. J. Immunol. 162 (1999) 2299-2307
70. de Haas C.J., et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med. 199 (2004) 687-695
71. Postma B., et al. Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J. Immunol. 172 (2004) 6994-7001
72. Haas P.J., et al. N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J. Immunol. 173 (2004) 5704-5711
73. Haas P.J., et al. The structure of the C5a receptor-blocking domain of chemotaxis inhibitory protein of Staphylococcus aureus is related to a group of immune evasive molecules. J. Mol. Biol. 353 (2005) 859-872
74. Postma B., et al. Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus. J. Biol. Chem. 280 (2005) 2020-2027
75. Czermak B.J., et al. Protective effects of C5a blockade in sepsis. Nat. Med. 5 (1999) 788-792
76. Pemberton M., et al. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J. Immunol. 150 (1993) 5104-5113
77. Prat C., et al. A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J. Immunol. 177 (2006) 8017-8026
78. Le Y., et al. Formyl-peptide receptors revisited. Trends Immunol. 23 (2002) 541-548
79. Geisbrecht B.V., et al. The crystal structures of EAP domains from Staphylococcus aureus reveal an unexpected homology to bacterial superantigens. J. Biol. Chem. 280 (2005) 17243-17250
80. Kaneider N.C., et al. Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J. 273 (2006) 4416-4424
81. Heying R., et al. Fibronectin-binding proteins and clumping factor A in Staphylococcus aureus experimental endocarditis: FnBPA is sufficient to activate human endothelial cells. Thromb. Haemost. 97 (2007) 617-626
82. Clarke S.R., and Foster S.J. Surface adhesins of Staphylococcus aureus. Adv. Microb. Physiol. 51 (2006) 187-224
83. O'Brien L.M. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell. Microbiol. 4 (2002) 759-770
84. Patti J.M., et al. The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect. Immun. 62 (1994) 152-161
85. Sabat A., et al. Distribution of the serine-aspartate repeat protein-encoding sdr genes among nasal-carriage and invasive Staphylococcus aureus strains. J. Clin. Microbiol. 44 (2006) 1135-1138
86. Roche F.M., et al. The Staphylococcus aureus surface protein SasG and its homologues promote bacterial adherence to human desquamated nasal epithelial cells. Microbiology 149 (2003) 2759-2767
87. Hartleib J., et al. Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood 96 (2000) 2149-2156
88. Nguyen T., et al. Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. Infect. Immun. 68 (2000) 2061-2068
89. Panizzi P., et al. Fibrinogen substrate recognition by staphylocoagulase (pro)thrombin complexes. J. Biol. Chem. 281 (2006) 1179-1187
90. Sawai T., et al. Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect. Immun. 65 (1997) 466-471
91. Hussain M., et al. Identification and characterization of a novel 38.5-kilodalton cell surface protein of Staphylococcus aureus with extended-spectrum binding activity for extracellular matrix and plasma proteins. J. Bacteriol. 183 (2001) 6778-6786
92. Shannon O., et al. Extracellular fibrinogen binding protein, Efb, from Staphylococcus aureus as an antiplatelet agent in vivo. Thromb. Haemost. 93 (2005) 927-931
93. Clarke S.R., et al. IsdA of Staphylococcus aureus is a broad spectrum, iron-regulated adhesion. Mol. Microbiol. 51 (2004) 1509-1519
94. Zhang L., et al. A second IgG-binding protein in Staphylococcus aureus. Microbiology 144 (1998) 985-991
95. Cosgrove K., et al. Catalase (KatA) and alkyl hydroperoxide reductase (AhpC) have compensatory roles in peroxide stress resistance and are required for survival, persistence, and nasal colonization in Staphylococcus aureus. J. Bacteriol. 189 (2007) 1025-1035
96. Roos G., et al. The conserved active site proline determines the reducing power of Staphylococcus aureus thioredoxin. J. Mol. Biol. 368 (2007) 800-811
97. Rollof J., et al. Interference of Staphylococcus aureus lipase with human granulocyte function. Eur. J. Clin. Microbiol. Infect. Dis. 7 (1988) 505-510
98. Kapral F.A., et al. The esterification of fatty acids by Staphylococcus aureus fatty acid modifying enzyme (FAME) and its inhibition by glycerides. J. Med. Microbiol. 37 (1992) 235-237
99. Shaw L., et al. The role and regulation of the extracellular proteases of Staphylococcus aureus. Microbiology 150 (2004) 217-228
100. Marques M.B., et al. Phosphatidylinositol-specific phospholipase C, a possible virulence factor of Staphylococcus aureus. J. Clin. Microbiol. 27 (1989) 2451-2454
101. Carneiro C.R., et al. Identification of enolase as a laminin-binding protein on the surface of Staphylococcus aureus. Microbes Infect. 6 (2004) 604-608
102. Clauditz A., et al. Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress. Infect. Immun. 74 (2006) 4950-4953
103. Fournier B., and Philpott D.J. Recognition of Staphylococcus aureus by the innate immune system. Clin. Microbiol. Rev. 18 (2005) 521-540
104. Somerville G.A., et al. Synthesis and deformylation of Staphylococcus aureus delta-toxin are linked to tricarboxylic acid cycle activity. J. Bacteriol. 185 (2003) 6686-6694
105. Thomas D., et al. Diversity in Staphylococcus aureus enterotoxins. Chem. Immunol. Allergy 93 (2007) 24-41
106. Peterson P.K., et al. Dichotomy between opsonization and serum complement activation by encapsulated staphylococci. Infect. Immun. 20 (1978) 770-775
107. Fedtke I., et al. Bacterial evasion of innate host defenses - the Staphylococcus aureus lesson. Int. J. Med. Microbiol. 294 (2004) 189-194
108. Peschel A., et al. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274 (1999) 8405-8410
109. Hunt C.L., et al. Effect of D-alanylation of (lipo)teichoic acids of Staphylococcus aureus on host secretory phospholipase A2 action before and after phagocytosis by human neutrophils. J. Immunol. 176 (2006) 4987-4994
110. Kristian S.A., et al. MprF-mediated lysinylation of phospholipids in Staphylococcus aureus leads to protection against oxygen-independent neutrophil killing. Infect. Immun. 71 (2003) 546-549